PMID- 28760652
OWN - NLM
STAT- MEDLINE
DCOM- 20180523
LR  - 20180523
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 31
IP  - 10
DP  - 2017 Oct
TI  - Serum amyloid A enrichment impairs the anti-inflammatory ability of HDL from 
      diabetic nephropathy patients.
PG  - 1538-1543
LID - S1056-8727(17)30504-4 [pii]
LID - 10.1016/j.jdiacomp.2017.07.005 [doi]
AB  - AIMS: Impaired anti-inflammatory ability of high-density lipoprotein (HDL) has 
      been demonstrated in patients with type-2 diabetes mellitus (T2DM). However, 
      whether HDL from patients with diabetic nephropathy (DN) suffers additional 
      damage remains unknown. This study compared the anti-inflammatory capacities of 
      HDL from healthy controls, T2DM patients with normal renal function, and T2DM 
      patients with DN. MATERIALS AND METHODS: HDL was isolated from healthy controls 
      (n=33) and T2DM patients with normal renal function (n=21), chronic kidney 
      disease (CKD) (n=27), and end-stage renal disease (ESRD) (n=27). Human peripheral 
      blood mononuclear cells (PBMCs) from healthy volunteers were pretreated with HDL 
      (100mug/mL) for 1h, then incubated with lipopolysaccharide (LPS) (50ng/mL) for 
      24h. The anti-inflammatory ability of HDL was measured as the secretion of TNF-alpha 
      in LPS-activated monocytes. RESULTS: The anti-inflammatory ability of HDL was 
      gradually impaired as kidney function declined. Serum amyloid A (SAA) 
      concentration in HDL(DN) significantly increased and was positively correlated 
      with the impaired anti-inflammatory ability of HDL (Pearson r=0.315, P=0.006). 
      Furthermore, HDL supplemented with SAA significantly increased TNF-alpha release from 
      PBMCs compared with that from control HDL. CONCLUSIONS: These findings identified 
      an impaired anti-inflammatory capacity of HDL from DN patients, which might be 
      attributable to SAA enrichment.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Mao, Jing Yan
AU  - Mao JY
AD  - Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory 
      for Tumor Microenvironment and Inflammation, Key Laboratory of Cell 
      Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 200025, China.
FAU - Sun, Jia Teng
AU  - Sun JT
AD  - Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai 200025, China.
FAU - Yang, Ke
AU  - Yang K
AD  - Institute of Cardiovascular Disease, Shanghai Jiao Tong University School of 
      Medicine, Shanghai 200025, China.
FAU - Shen, Wei Feng
AU  - Shen WF
AD  - Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai 200025, China; Institute of Cardiovascular Disease, 
      Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
FAU - Lu, Lin
AU  - Lu L
AD  - Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai 200025, China.
FAU - Zhang, Rui Yan
AU  - Zhang RY
AD  - Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai 200025, China.
FAU - Tong, Xuemei
AU  - Tong X
AD  - Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory 
      for Tumor Microenvironment and Inflammation, Key Laboratory of Cell 
      Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 200025, China. Electronic address: 
      xuemeitong@shsmu.edu.cn.
FAU - Liu, Yan
AU  - Liu Y
AD  - Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 200011, China. Electronic address: 
      liuyan_ivy@126.com.
LA  - eng
PT  - Journal Article
DEP - 20170713
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Serum Amyloid A Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cells, Cultured
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Angiopathies/epidemiology/immunology/*metabolism/pathology
MH  - Diabetic Nephropathies/immunology/*metabolism/pathology/physiopathology
MH  - Female
MH  - Hospitals, University
MH  - Humans
MH  - Kidney/physiopathology
MH  - Kidney Failure, Chronic/complications/immunology/metabolism/pathology
MH  - Leukocytes, Mononuclear/drug effects/immunology/metabolism/pathology
MH  - Lipopolysaccharides/toxicity
MH  - Lipoproteins, HDL/*blood/isolation & purification/metabolism
MH  - Male
MH  - Middle Aged
MH  - Outpatient Clinics, Hospital
MH  - Renal Insufficiency, Chronic/complications/immunology/metabolism/pathology
MH  - Risk Factors
MH  - Serum Amyloid A Protein/*analysis/metabolism
MH  - Severity of Illness Index
MH  - Vasculitis/*complications/immunology/metabolism/pathology
OTO - NOTNLM
OT  - Anti-inflammatory
OT  - Cardiovascular disease
OT  - Diabetic nephropathy
OT  - High-density lipoprotein
OT  - Serum amyloid A
EDAT- 2017/08/02 06:00
MHDA- 2018/05/24 06:00
CRDT- 2017/08/02 06:00
PHST- 2017/04/07 00:00 [received]
PHST- 2017/07/06 00:00 [revised]
PHST- 2017/07/07 00:00 [accepted]
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2018/05/24 06:00 [medline]
PHST- 2017/08/02 06:00 [entrez]
AID - S1056-8727(17)30504-4 [pii]
AID - 10.1016/j.jdiacomp.2017.07.005 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2017 Oct;31(10):1538-1543. doi: 
      10.1016/j.jdiacomp.2017.07.005. Epub 2017 Jul 13.